Cargando…

Diagnostic accuracy of a point‐of‐care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz‐based antiretroviral therapy

INTRODUCTION: Novel point‐of‐care assays which measure urine tenofovir (TFV) concentrations may have a role in improving adherence monitoring for people living with HIV (PLHIV) receiving antiretroviral therapy (ART). However, further studies of their diagnostic accuracy, and whether results are asso...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dorward, Jienchi, Lessells, Richard, Govender, Katya, Moodley, Pravi, Samsunder, Natasha, Sookrajh, Yukteshwar, Turner, Phil, Butler, Christopher C., Hayward, Gail, Gandhi, Monica, Drain, Paul K., Garrett, Nigel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514373/ https://www.ncbi.nlm.nih.gov/pubmed/37735860 http://dx.doi.org/10.1002/jia2.26172

Ejemplares similares

Clinical Outcomes After Viremia Among People Receiving Dolutegravir vs Efavirenz-Based First-line Antiretroviral Therapy in South Africa
por: Asare, Kwabena, et al.
Publicado: (2023)

Point-of-Care Viral Load Testing to Manage HIV Viremia During the Rollout of Dolutegravir-Based ART in South Africa: A Randomized Feasibility Study (POwER)
por: Dorward, Jienchi, et al.
Publicado: (2023)

Diagnostic accuracy of the rapid Xpert HIV-1 Viral Load XC, Xpert HIV-1 Viral Load & m-PIMA HIV-1/2 Viral Load in South African clinics
por: DORWARD, Jienchi, et al.
Publicado: (2022)

Protocol for a randomised feasibility study of Point-Of-care HIV viral load testing to Enhance Re-suppression in South Africa: the POwER study
por: Dorward, Jienchi, et al.
Publicado: (2021)

Simplifying TREAtment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes
por: Bardon, Ashley R, et al.
Publicado: (2021)

Clinical outcomes after the introduction of dolutegravir for second-line antiretroviral therapy in South Africa: a retrospective cohort study
por: Asare, Kwabena, et al.
Publicado: (2023)

IMPLEMENTATION AND OUTCOMES OF DOLUTEGRAVIR-BASED FIRST-LINE ANTIRETROVIRAL THERAPY FOR PEOPLE WITH HIV IN SOUTH AFRICA: A RETROSPECTIVE COHORT STUDY
por: Dorward, Jienchi, et al.
Publicado: (2023)

Low CD4 count and educational status predict abnormal cervical smears amongst HIV-positive women initiating antiretroviral therapy in South Africa
por: Mthembu, Nondumiso, et al.
Publicado: (2020)

Diagnostic accuracy of the Alere Afinion AS100 point-of-care assay to screen for non-communicable diseases amongst people living with HIV
por: Bodley, Nicola, et al.
Publicado: (2022)

Clinic flow for STI, HIV, and TB patients in an urban infectious disease clinic offering point-of-care testing services in Durban, South Africa
por: Stime, Katrina J., et al.
Publicado: (2018)

Delivery of Community-based Antiretroviral Therapy to Maintain Viral Suppression and Retention in Care in South Africa
por: Wang, Melody, et al.
Publicado: (2023)

HIV treatment outcomes among people with initiation CD4 counts >500 cells/µL after implementation of Treat All in South African public clinics: a retrospective cohort study
por: Dorward, Jienchi, et al.
Publicado: (2020)

Comparative cost analysis of point-of-care versus laboratory-based testing to initiate and monitor HIV treatment in South Africa
por: Simeon, Kate, et al.
Publicado: (2019)

Low-level viraemia despite emergence of dolutegravir-resistant variants
por: Botha, Johannes C., et al.
Publicado: (2022)

Differentiated service delivery for people using second‐line antiretroviral therapy: clinical outcomes from a retrospective cohort study in KwaZulu‐Natal, South Africa
por: Lewis, Lara, et al.
Publicado: (2021)

Clinical outcomes after extended 12‐month antiretroviral therapy prescriptions in a community‐based differentiated HIV service delivery programme in South Africa: a retrospective cohort study
por: Lewis, Lara, et al.
Publicado: (2023)

Long‐term usage patterns and clinical outcomes in a community‐based differentiated antiretroviral therapy delivery programme in South Africa
por: Lewis, Lara, et al.
Publicado: (2023)

Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
por: Deng, Lisi, et al.
Publicado: (2022)

The impact of the COVID-19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series analysis
por: Dorward, Jienchi, et al.
Publicado: (2021)

Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults
por: Li, Jin, et al.
Publicado: (2022)

Acute Liver Toxicity due to Efavirenz/Emtricitabine/Tenofovir
por: Patil, Rashmee, et al.
Publicado: (2015)

Protocol for a randomised controlled implementation trial of point-of-care viral load testing and task shifting: the Simplifying HIV TREAtment and Monitoring (STREAM) study
por: Dorward, Jienchi, et al.
Publicado: (2017)

Understanding how community antiretroviral delivery influences engagement in HIV care: a qualitative assessment of the Centralised Chronic Medication Dispensing and Distribution programme in South Africa
por: Dorward, Jienchi, et al.
Publicado: (2020)

Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks
por: Tebas, Pablo, et al.
Publicado: (2015)

48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial
por: Yazdanpanah, Y, et al.
Publicado: (2014)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy
por: Griesel, Rulan, et al.
Publicado: (2022)

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020)

Antiretroviral drugs efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function
por: Huang, Chang, et al.
Publicado: (2023)

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
por: Sax, Paul E., et al.
Publicado: (2018)

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
por: Restelli, Umberto, et al.
Publicado: (2017)

Tenofovir-Diphosphate in Dried Blood Spots vs Tenofovir in Urine/Plasma for Oral Preexposure Prophylaxis Adherence Monitoring
por: Niu, Xin, et al.
Publicado: (2022)

Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir
por: Khemla, Supphachoke, et al.
Publicado: (2023)

Acceptability of point-of-care viral load testing to facilitate differentiated care: a qualitative assessment of people living with HIV and nurses in South Africa
por: Msimango, Lindani, et al.
Publicado: (2020)

Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide–Based Regimens
por: Batterham, Rachel L, et al.
Publicado: (2023)

Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing
por: Johnson, Kelly A, et al.
Publicado: (2021)

Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment
por: Steegen, Kim, et al.
Publicado: (2022)

Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda
por: Twimukye, Adelline, et al.
Publicado: (2021)

Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults
por: Lamorde, Mohammed, et al.
Publicado: (2012)

First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir/lamivudine/dolutegravir use in mothers
por: Francois, Kesner, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dthrt158e407rcvkbkcah00alb